Another big Vertex challenger suffers a TKO. And that will cause some problems for the CF champ
You almost have to feel sorry for the R&D groups that try to challenge Vertex’s $10 billion cystic fibrosis franchise. Even if it’s a quite capable market brawler like AbbVie.
Yesterday, AbbVie R&D chief Tom Hudson shrugged off a major setback for the company, noting that its mid-stage CF triple had failed an interim review “and we are discontinuing our cystic fibrosis program.”
After an earlier failure, this one is kaput.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.